Switch to:
Also traded in: Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.18
BAYRY's Cash to Debt is ranked lower than
84% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. BAYRY: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
BAYRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.29 Max: No Debt
Current: 0.18
Equity to Asset 0.31
BAYRY's Equity to Asset is ranked lower than
88% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BAYRY: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
BAYRY' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.35 Max: 0.46
Current: 0.31
0.21
0.46
Interest Coverage 7.20
BAYRY's Interest Coverage is ranked lower than
78% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.94 vs. BAYRY: 7.20 )
Ranked among companies with meaningful Interest Coverage only.
BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.57  Med: 5.71 Max: N/A
Current: 7.2
F-Score: 7
Z-Score: 1.98
M-Score: -2.61
WACC vs ROIC
7.50%
10.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.95
BAYRY's Operating margin (%) is ranked higher than
61% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.61 vs. BAYRY: 11.95 )
Ranked among companies with meaningful Operating margin (%) only.
BAYRY' s Operating margin (%) Range Over the Past 10 Years
Min: 7.78  Med: 10.11 Max: 11.36
Current: 11.95
7.78
11.36
Net-margin (%) 10.08
BAYRY's Net-margin (%) is ranked higher than
64% of the 732 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. BAYRY: 10.08 )
Ranked among companies with meaningful Net-margin (%) only.
BAYRY' s Net-margin (%) Range Over the Past 10 Years
Min: 3.71  Med: 6.41 Max: 14.55
Current: 10.08
3.71
14.55
ROE (%) 20.14
BAYRY's ROE (%) is ranked higher than
83% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. BAYRY: 20.14 )
Ranked among companies with meaningful ROE (%) only.
BAYRY' s ROE (%) Range Over the Past 10 Years
Min: 6.9  Med: 13.68 Max: 31.94
Current: 20.14
6.9
31.94
ROA (%) 6.22
BAYRY's ROA (%) is ranked higher than
65% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. BAYRY: 6.22 )
Ranked among companies with meaningful ROA (%) only.
BAYRY' s ROA (%) Range Over the Past 10 Years
Min: 2.54  Med: 4.68 Max: 8.78
Current: 6.22
2.54
8.78
ROC (Joel Greenblatt) (%) 32.88
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.31 vs. BAYRY: 32.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAYRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.91  Med: 25.65 Max: 33.37
Current: 32.88
17.91
33.37
Revenue Growth (3Y)(%) 5.20
BAYRY's Revenue Growth (3Y)(%) is ranked higher than
50% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. BAYRY: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAYRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.6  Med: 2.6 Max: 11.1
Current: 5.2
-10.6
11.1
EBITDA Growth (3Y)(%) 14.90
BAYRY's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. BAYRY: 14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BAYRY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 3.2 Max: 15.4
Current: 14.9
-9.9
15.4
EPS Growth (3Y)(%) 18.70
BAYRY's EPS Growth (3Y)(%) is ranked higher than
66% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. BAYRY: 18.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAYRY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.1  Med: 8.9 Max: 39.3
Current: 18.7
-19.1
39.3
GuruFocus has detected 5 Warning Signs with Bayer AG $BAYRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BAYRY Guru Trades in Q1 2016

Ken Fisher 4,833,445 sh (+2.63%)
» More
Q2 2016

BAYRY Guru Trades in Q2 2016

Ken Fisher 4,909,612 sh (+1.58%)
» More
Q3 2016

BAYRY Guru Trades in Q3 2016

Ken Fisher 4,927,034 sh (+0.35%)
» More
Q4 2016

BAYRY Guru Trades in Q4 2016

Ken Fisher 4,859,655 sh (-1.37%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:GLAXF, NYSE:LLY, NYSE:BMY, NYSE:ABBV, NYSE:SNY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, NYSE:NVS, OTCPK:OPHLY, NYSE:MRK, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF, NAS:HCM, OTCPK:HAWPF » details
Traded in other countries:BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Bayer AG is a research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences and crop sciences.

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.

Top Ranked Articles about Bayer AG

Monsanto Posts Profitable Quarter From South American Growth Company’s merger with Bayer remains on track
Monsanto Co. (NYSE:MON) posted strong first-quarter results for fiscal 2017 on Thursday, returning to profitability after battling a multiyear decline in the prices of corn, soybeans and other major crops. Read more...
Warren Buffett's Financial Engineering For decades Buffett used borrowed money and this strategy to crush the market
Investors often overlook the financial engineering that Warren Buffett (Trades, Portfolio) has employed throughout the years that helped build his personal fortune and the book value of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B). Read more...
Will the Monsanto-Bayer Deal Go Through? There are too many groups opposed to the merger
Bayer (BAYRY) has offered to buy Monsanto (NYSE:MON) for $128 a share, yet the market value of Monsanto is only $102.48. Evidently, the market does not think this deal is going to go through. Neither do I. Read more...
Monsanto Agrees to Bayer’s Proposal Merger would be largest foreign takeover by a German company
A proposed deal from Bayer (BAYRY) to buy Monsanto (NYSE:MON) was approved Wednesday. The deal will consolidate two of the world’s six agricultural giants. Read more...
Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Analyzing the buying and selling of Monsanto shares to determine what 5 gurus expect from Bayer’s attempts to buy company
This week or next, a proposed deal in which Bayer AG (BAYRY) would buy the Monsanto Company (NYSE:MON) is expected to get the nod or get the boot. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.08
BAYRY's P/E(ttm) is ranked higher than
73% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. BAYRY: 18.08 )
Ranked among companies with meaningful P/E(ttm) only.
BAYRY' s P/E(ttm) Range Over the Past 10 Years
Min: 8.01  Med: 22.74 Max: 38.59
Current: 18.08
8.01
38.59
Forward P/E 12.76
BAYRY's Forward P/E is ranked higher than
69% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.95 vs. BAYRY: 12.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.70
BAYRY's PE(NRI) is ranked higher than
71% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. BAYRY: 18.70 )
Ranked among companies with meaningful PE(NRI) only.
BAYRY' s PE(NRI) Range Over the Past 10 Years
Min: 14.77  Med: 23.49 Max: 38.59
Current: 18.7
14.77
38.59
Price/Owner Earnings (ttm) 18.07
BAYRY's Price/Owner Earnings (ttm) is ranked higher than
74% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.46 vs. BAYRY: 18.07 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BAYRY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.35  Med: 16.12 Max: 31.13
Current: 18.07
7.35
31.13
P/B 3.62
BAYRY's P/B is ranked lower than
61% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. BAYRY: 3.62 )
Ranked among companies with meaningful P/B only.
BAYRY' s P/B Range Over the Past 10 Years
Min: 1.54  Med: 2.58 Max: 5.55
Current: 3.62
1.54
5.55
P/S 1.82
BAYRY's P/S is ranked higher than
65% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.91 vs. BAYRY: 1.82 )
Ranked among companies with meaningful P/S only.
BAYRY' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 1.38 Max: 2.82
Current: 1.82
0.87
2.82
PFCF 14.86
BAYRY's PFCF is ranked higher than
68% of the 200 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.43 vs. BAYRY: 14.86 )
Ranked among companies with meaningful PFCF only.
BAYRY' s PFCF Range Over the Past 10 Years
Min: 7.27  Med: 19.61 Max: 248.88
Current: 14.86
7.27
248.88
POCF 10.30
BAYRY's POCF is ranked higher than
72% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.46 vs. BAYRY: 10.30 )
Ranked among companies with meaningful POCF only.
BAYRY' s POCF Range Over the Past 10 Years
Min: 5.51  Med: 9.84 Max: 19.39
Current: 10.3
5.51
19.39
EV-to-EBIT 15.47
BAYRY's EV-to-EBIT is ranked higher than
67% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.56 vs. BAYRY: 15.47 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 17.3 Max: 29.4
Current: 15.47
7.8
29.4
EV-to-EBITDA 10.03
BAYRY's EV-to-EBITDA is ranked higher than
77% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.22 vs. BAYRY: 10.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 9.8 Max: 17.9
Current: 10.03
4.4
17.9
PEG 2.46
BAYRY's PEG is ranked lower than
58% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.91 vs. BAYRY: 2.46 )
Ranked among companies with meaningful PEG only.
BAYRY' s PEG Range Over the Past 10 Years
Min: 1.14  Med: 3.4 Max: 469.75
Current: 2.46
1.14
469.75
Shiller P/E 27.57
BAYRY's Shiller P/E is ranked higher than
72% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.99 vs. BAYRY: 27.57 )
Ranked among companies with meaningful Shiller P/E only.
BAYRY' s Shiller P/E Range Over the Past 10 Years
Min: 16.81  Med: 28.83 Max: 42.62
Current: 27.57
16.81
42.62
Current Ratio 1.51
BAYRY's Current Ratio is ranked lower than
71% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. BAYRY: 1.51 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.51 Max: 2.13
Current: 1.51
1
2.13
Quick Ratio 1.01
BAYRY's Quick Ratio is ranked lower than
75% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. BAYRY: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.01 Max: 1.44
Current: 1.01
0.64
1.44
Days Inventory 151.50
BAYRY's Days Inventory is ranked lower than
67% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. BAYRY: 151.50 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.65  Med: 138.65 Max: 154.01
Current: 151.5
126.65
154.01
Days Sales Outstanding 84.37
BAYRY's Days Sales Outstanding is ranked lower than
58% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.25 vs. BAYRY: 84.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.71  Med: 69.96 Max: 80.32
Current: 84.37
65.71
80.32
Days Payable 87.98
BAYRY's Days Payable is ranked higher than
63% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.85 vs. BAYRY: 87.98 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 54.65  Med: 75.75 Max: 102.56
Current: 87.98
54.65
102.56

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.62
BAYRY's Dividend Yield is ranked higher than
72% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. BAYRY: 2.62 )
Ranked among companies with meaningful Dividend Yield only.
BAYRY' s Dividend Yield Range Over the Past 10 Years
Min: 1.44  Med: 2.39 Max: 3.93
Current: 2.62
1.44
3.93
Dividend Payout 0.46
BAYRY's Dividend Payout is ranked lower than
64% of the 389 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. BAYRY: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
BAYRY' s Dividend Payout Range Over the Past 10 Years
Min: 0.36  Med: 0.51 Max: 0.89
Current: 0.46
0.36
0.89
Dividend Growth (3y) 10.90
BAYRY's Dividend Growth (3y) is ranked higher than
57% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. BAYRY: 10.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAYRY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.6 Max: 34.9
Current: 10.9
0
34.9
Forward Dividend Yield 2.62
BAYRY's Forward Dividend Yield is ranked higher than
66% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. BAYRY: 2.62 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.37
BAYRY's Yield on cost (5-Year) is ranked higher than
80% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.17 vs. BAYRY: 4.37 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAYRY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.38  Med: 3.96 Max: 6.5
Current: 4.37
2.38
6.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.54
BAYRY's Price/Projected FCF is ranked higher than
72% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. BAYRY: 1.54 )
Ranked among companies with meaningful Price/Projected FCF only.
BAYRY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.77 Max: 4.09
Current: 1.54
0.8
4.09
Price/DCF (Earnings Based) 1.32
BAYRY's Price/DCF (Earnings Based) is ranked higher than
52% of the 77 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. BAYRY: 1.32 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.32
BAYRY's Price/Median PS Value is ranked lower than
62% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. BAYRY: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
BAYRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.89 Max: 1.95
Current: 1.32
0.23
1.95
Price/Peter Lynch Fair Value 1.73
BAYRY's Price/Peter Lynch Fair Value is ranked lower than
51% of the 150 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. BAYRY: 1.73 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BAYRY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.7  Med: 2.17 Max: 5.7
Current: 1.73
0.7
5.7
Earnings Yield (Greenblatt) (%) 6.50
BAYRY's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. BAYRY: 6.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAYRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.4  Med: 5.8 Max: 12.9
Current: 6.5
3.4
12.9
Forward Rate of Return (Yacktman) (%) 15.26
BAYRY's Forward Rate of Return (Yacktman) (%) is ranked higher than
65% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.63 vs. BAYRY: 15.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAYRY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.4  Med: 9 Max: 26.4
Current: 15.26
-11.4
26.4

More Statistics

Revenue (TTM) (Mil) $51,786
EPS (TTM) $ 6.33
Beta1.10
Short Percentage of Float0.01%
52-Week Range $91.53 - 125.20
Shares Outstanding (Mil)826.95

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 49,206 51,434 53,918
EPS ($) 7.86 8.52 9.21
EPS w/o NRI ($) 7.86 8.52 9.21
EPS Growth Rate
(3Y to 5Y Estimate)
7.99%
Dividends Per Share ($) 2.72 2.88 3.23
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
A Green Light on Bayer Jan 19 2017 
Monsanto Posts Profitable Quarter From South American Growth Jan 06 2017 
A Year in Review and Recommendations for 2017 Dec 27 2016 
Warren Buffett's Financial Engineering Nov 15 2016 
3 Chemical Companies From Polaris Global Value Oct 17 2016 
Will the Monsanto-Bayer Deal Go Through? Sep 20 2016 
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
Monsanto Agrees to Bayer’s Proposal Sep 15 2016 
Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Sep 13 2016 
Bestinfond’s 2nd Quarter Buys Sep 13 2016 

More From Other Websites
4:01 am Bayer AG receives Priority Review for Regorafenib in Japan Jan 20 2017
A Green Light on Bayer Jan 19 2017
German companies on a tear in U.S., energized by low interest rates and rebounding markets Jan 19 2017
Watchdogs Warn Trump on Bayer's Bid for Monsanto Jan 18 2017
Bayer will keep Monsanto jobs, invest billions in R&D if merger is approved: Report Jan 18 2017
Bayer pledges billions in US investments Jan 17 2017
Report: Bayer, Monsanto deal could be sweetened by additional investments, jobs Jan 17 2017
Bayer-Monsanto Pledge Investment, Jobs After Trump Meeting Jan 17 2017
Bayer to boost U.S. jobs, investments amid Monsanto deal - Trump spokesman Jan 17 2017
Bayer to boost U.S. jobs, investments amid Monsanto deal - Trump spokesman Jan 17 2017
Bayer to boost U.S. jobs, investments amid Monsanto deal: Trump spokesman Jan 17 2017
Bayer to boost U.S. jobs, investments amid Monsanto deal -Trump spokesman Jan 17 2017
RWE AG -- Moody's: German corporate credit quality to remain stable in 2017 Jan 16 2017
RWE AG -- Moody's: Bonität deutscher Industrieunternehmen auch 2017 stabil Jan 16 2017
Monsanto, Bayer CEOs Pitch $57B M&A Deal to Trump Jan 12 2017
Bayer says had productive meeting with Trump over Monsanto deal Jan 12 2017
Bayer says had productive meeting with Trump over Monsanto deal Jan 12 2017
'Stage Is Set' for M&A to Continue in 2017 Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)